Exposure to Infliximab During Pregnancy: Post-Marketing Experience

BACKGROUND: Women of childbearing potential are often treated with monoclonal antibodies to control chronic and debilitating inflammatory diseases. Remicade(®) (innovator infliximab [IFX]) may cross the placenta after the first trimester of pregnancy. Hence, evidence is needed to optimize treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Geldhof, Anja, Slater, Jennifer, Clark, Michael, Chandran, Urmila, Coppola, Danielle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7007430/
https://www.ncbi.nlm.nih.gov/pubmed/31677004
http://dx.doi.org/10.1007/s40264-019-00881-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7007430/
https://www.ncbi.nlm.nih.gov/pubmed/31677004
http://dx.doi.org/10.1007/s40264-019-00881-8

Ejemplares similares